Nature Communications

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial

2025-12-23

Full text

DOI https://doi.org/10.1038/s41467-025-66097-w